Mesoblast Limited (MESO)
MESO Stock Price Chart
Explore Mesoblast Limited interactive price chart. Choose custom timeframes to analyze MESO price movements and trends.
MESO Company Profile
Discover essential business fundamentals and corporate details for Mesoblast Limited (MESO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Jan 2010
Employees
73.00
Website
https://www.mesoblast.comCEO
Silviu Itescu
Description
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.
MESO Financial Timeline
Browse a chronological timeline of Mesoblast Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Sept 2026
EPS estimate is -$0.10, while revenue estimate is $73.42m.
Earnings released on 26 Feb 2026
EPS came in at -$0.31 falling short of the estimated -$0.24 by -31.22%, while revenue for the quarter reached $51.34m , missing expectations by -3.25%.
Earnings released on 28 Aug 2025
EPS came in at -$0.32 falling short of the estimated -$0.20 by -60.00%, while revenue for the quarter reached $15.58m , beating expectations by +10.24%.
Earnings released on 29 Jul 2025
EPS came in at -$0.43 falling short of the estimated -$0.37 by -15.18%, while revenue for the quarter reached $14.02m , missing expectations by -0.77%.
Earnings released on 30 Apr 2025
EPS came in at -$0.21 surpassing the estimated -$0.35 by +38.28%, while revenue for the quarter reached $7.02m , missing expectations by -6.15%.
Earnings released on 26 Feb 2025
EPS came in at -$0.42 falling short of the estimated -$0.25 by -68.00%, while revenue for the quarter reached $3.20m , beating expectations by +7.25%.
Earnings released on 30 Oct 2024
EPS came in at -$0.28 surpassing the estimated -$0.31 by +9.68%, while revenue for the quarter reached $1.58m , missing expectations by -54.52%.
Earnings released on 29 Aug 2024
EPS came in at -$0.28 surpassing the estimated -$0.31 by +9.68%, while revenue for the quarter reached $1.26m , missing expectations by -90.54%.
Earnings released on 4 Jul 2024
EPS came in at -$0.26 surpassing the estimated -$0.35 by +25.71%, while revenue for the quarter reached $2.51m , missing expectations by -34.23%.
Earnings released on 13 Jun 2024
EPS came in at -$0.38 surpassing the estimated -$0.43 by +10.43%, while revenue for the quarter reached $3.39m , missing expectations by -12.43%.
Earnings released on 4 Mar 2024
EPS came in at -$0.26 surpassing the estimated -$0.40 by +34.15%, while revenue for the quarter reached $5.61m , beating expectations by +0.16%.
Stock split effective on 10 Jan 2024
Shares were split 1 : 2 , changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 5 Dec 2023
Shares were split 529 : 500 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Aug 2023
EPS came in at -$0.28 surpassing the estimated -$0.32 by +12.50%, while revenue for the quarter reached $1.90m , missing expectations by -20.28%.
Earnings released on 25 May 2023
EPS came in at -$0.26 surpassing the estimated -$0.36 by +27.78%, while revenue for the quarter reached $1.94m , missing expectations by -9.38%.
Earnings released on 27 Feb 2023
EPS came in at -$0.34 falling short of the estimated -$0.30 by -13.33%, while revenue for the quarter reached $2.13m , beating expectations by +1.62%.
Earnings released on 22 Nov 2022
EPS came in at -$0.24 falling short of the estimated -$0.20 by -20.00%, while revenue for the quarter reached $1.50m , missing expectations by -56.64%.
Earnings released on 30 Aug 2022
EPS came in at -$0.34 falling short of the estimated -$0.10 by -240.00%, while revenue for the quarter reached $2.21m , missing expectations by -70.86%.
Earnings released on 31 May 2022
EPS came in at -$0.32 falling short of the estimated -$0.16 by -100.00%, while revenue for the quarter reached $2.01m , missing expectations by -4.24%.
Earnings released on 24 Feb 2022
EPS came in at -$0.40 falling short of the estimated -$0.39 by -3.74%, while revenue for the quarter reached $2.38m , missing expectations by -31.91%.
Earnings released on 23 Nov 2021
EPS came in at -$0.34 falling short of the estimated -$0.30 by -13.33%, while revenue for the quarter reached $3.59m , beating expectations by +46.10%.
Earnings released on 31 Aug 2021
EPS came in at -$0.34 falling short of the estimated -$0.18 by -83.89%, while revenue for the quarter reached $2.00m , beating expectations by +6.72%.
MESO Stock Performance
Access detailed MESO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
